Solid-Phase Synthesis of Biaryl Cyclic Peptides: Unlocking New Frontiers in Peptide Therapeutics

Why do 90% of peptide-based drugs fail in clinical trials? The answer often lies in their structural instability and poor bioavailability. Traditional linear peptides face rapid enzymatic degradation, creating a critical need for cyclic structures with enhanced stability.